COPD治療薬tozorakimabの第3相2試験結果をAstraZenecaが発表──増悪抑制効果と好酸球別解析
stellanews.life/technology/1... #tozorakimab #OBERON
@yoshitakahoshi.bsky.social
@yoshitakahoshi.bsky.socialCOPD治療薬tozorakimabの第3相2試験結果をAstraZenecaが発表──増悪抑制効果と好酸球別解析
stellanews.life/technology/1... #tozorakimab #OBERON
@emg-gold.comStudy results: AstraZeneca drug holds promise in #COPD.
The trial showed that #tozorakimab cut moderate-to-severe exacerbations significantly in former smokers, the trials’ primary population, compared with placebo.
Discover more: www.emjreviews.com/emj-gold/new...
@medchemexpress.bsky.socialA new NEJM study reports promising Phase 3 results for #tozorakimab, an IL-33–targeting monoclonal antibody, in patients with COPD.
📊Across the OBERON and TITANIA trials, tozorakimab reduced the rate of moderate-to-severe COPD exacerbations by ~30% versus placebo.
@bionewscentral.comTwo international #ClinicalTrials found that the investigational #BiologicTherapy #tozorakimab significantly reduced #COPD flare-ups in patients receiving standard treatment.
#LungDisease
@globalvisibility.bsky.social
@pharmaphorum.bsky.socialThe #FDA has started a #priorityreview of #AstraZeneca's IL-33-targeting antibody #tozorakimab for chronic obstructive pulmonary disease (#COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027.
